Identification and Prognostic Effect of Extramural Venous Invasion in Locally Advanced Esophageal Squamous Cell Carcinoma

被引:0
作者
Lin, Zhen [1 ,3 ]
Plukker, John T. M. [4 ]
Tian, Dong-ping [1 ]
Chen, Shao-bin [2 ]
Kats-Ugurlu, Gursah [3 ]
Su, Min [1 ]
机构
[1] Shantou Univ, Med Coll, Inst Clin Pathol, Guangdong Prov Key Lab Infect Dis & Mol Immunopath, Shantou, Peoples R China
[2] Shantou Univ, Canc Hosp, Med Coll, Dept Thorac Surg, Shantou, Peoples R China
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Surg Oncol, Groningen, Netherlands
基金
中国国家自然科学基金;
关键词
extramural venous invasion; esophageal squamous cell carcinoma; recurrence and survival; VASCULAR INVASION; RECTAL-CANCER; LYMPHOVASCULAR INVASION; NEOADJUVANT THERAPY; SURVIVAL; EMVI; TUMOR; STAIN; RISK;
D O I
10.1097/PAS.0000000000002048
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The role of extramural venous invasion (EMVI) in esophageal cancer is still unclear. This study aimed to identify EMVI and assess its impact on survival and recurrences in esophageal squamous cell carcinoma (ESCC). Retrospectively, we reviewed resection specimens of 147 locally advanced ESCC (pT3-T4aN0-3M0) patients who had a curative intended surgery alone at the Cancer Hospital of Shantou University from March 2009 to December 2013. After confirming pT & GE;3 in hematoxylin-eosin tumor slides, EMVI was evaluated by Verhoeff and Caldesmon staining. The impact of EMVI with other clinicopathological characteristics and survival were analyzed using the & chi;(2) test, Cox regression, and Kaplan-Meier method. EMVI was present in 30.6% (45/147) of the P & GE;T3 ESCCs and associated with lymph-vascular invasion and poor differentiation grade (P<0.05). Disease-free survival and overall survival in patients with EMVI-absent tumors were about 2.0 times longer than in those with EMVI-present tumors. In pN0 patients, EMVI-presence was associated with poor overall survival (HR 4.829, 95% CI 1.434-16.26, P=0.003) and Disease-free Survival (HR 4.026, 95% CI 0.685-23.32, P=0.018). In pN1-3 patients, EMVI had no additional effect on survival. Conclusions EMVI has an independent adverse prognostic effect on survival in ESCC patients after surgery alone. EMVI should be included in pathology reports as it might contribute to identify high-risk patients for potential additional treatment.
引用
收藏
页码:766 / 773
页数:8
相关论文
共 50 条
  • [41] Lymph node ratio is a prognostic indicator for locally advanced esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy
    Chen, Pengcheng
    Wang, Liang
    Yang, Xun
    Feng, Jifeng
    BIOMOLECULES AND BIOMEDICINE, 2024, 24 (01): : 159 - 169
  • [42] Post-radiation circulating tumor DNA as a prognostic factor in locally advanced esophageal squamous cell carcinoma
    Jia, Ru
    Zhao, Chuan-Hua
    Li, Pan-Song
    Liu, Rong-Rui
    Zhang, Yun
    Chen, Hai-E
    Chang, Lian-Peng
    Gong, Yu-Hua
    Guan, Yan-Fang
    Yi, Xin
    Xu, Jian-Ming
    ONCOLOGY LETTERS, 2021, 21 (01)
  • [43] Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
    Yang, Peng
    Zhou, Xiao
    Yang, Xuefeng
    Wang, Yuefeng
    Sun, Tao
    Feng, Shiying
    Ma, Xianyou
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [44] Lymphovascular invasion as an independent prognostic indicator in radically resected thoracic esophageal squamous cell carcinoma
    Wang, Zhen
    Chen, Peng
    Wang, Feng
    Lin, Liyan
    Liu, Shuoyan
    THORACIC CANCER, 2019, 10 (02) : 150 - 155
  • [45] Patterns and prognostic predictive value of perineural invasion in esophageal squamous cell carcinoma
    Yu Ma
    Jie Chen
    Xi Yao
    Zhenzhen Li
    Wensheng Li
    Hongtao Wang
    Jianfei Zhu
    BMC Cancer, 22
  • [46] Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
    Chen, Chih-Yi
    Li, Chia-Chin
    Chien, Chun-Ru
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [47] Apatinib Combined with Paclitaxel and Cisplatin Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Zhao, Jidong
    He, Ming
    Li, Jie
    Li, Dan
    Zhao, Yang
    Li, Xinhui
    Zhang, Xiangmei
    Chen, Xin
    Liu, Yunjiang
    Zhao, Liyan
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (04) : 324 - 331
  • [48] Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma
    Huang, Jiang-Qiong
    Liang, Huan-Wei
    Liu, Yang
    Chen, Long
    Pei, Su
    Yu, Bin-Bin
    Pan, Xin-Bin
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
    Yang, Xinyu
    Yin, Hao
    Zhang, Shaoyuan
    Jiang, Tian
    Gu, Jianmin
    Jiao, Heng
    Wang, Hao
    Liang, Fei
    Xu, Songtao
    Fan, Hong
    Ding, Jianyong
    Ge, Di
    Wang, Qun
    Yin, Jun
    Tan, Lijie
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2025, 169 (01)
  • [50] Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma
    Zhang, Xiao-Fei
    Liu, Pei-Yi
    Zhang, Shu-Juan
    Zhao, Kuai-Le
    Zhao, Wei-Xin
    WORLD JOURNAL OF CLINICAL CASES, 2022, 10 (35) : 12804 - 12811